What Changes we may Expect in 2010 Hypertension Diagnosis and Management: Insights from the European Update Document

Title: What Changes we may Expect in 2010 Hypertension Diagnosis and Management: Insights from the European Update Document

Volume: 8 Issue: 6

Author(s): Giuseppe Mancia and Guido Grassi

Affiliation:

Keywords: Guidelines, antihypertensive treatment, clinical trials, blood pressure, control, Hypertension, non-cardiovascular disease, European Society of Cardiology, hypertension treatment, microalbuminuria, renal damage, Modification of Diet in Renal Disease, left ventricular hypertrophy, antihypertensive drug treatment, cardiovascular risk, diuretics, β-blockers, calcium antagonists, ace-inhibitors, angiotensin II receptor, systolic and diastolic blood pressure, Telmisartan, Ramipril, European Lacidipine Study on Atheroscle-rosis, renin, aliskiren, POLYPILL, aspirin, coronary heart disease

Abstract: In 2009, the European Society of Hypertension (ESH) has developed a document updating the recommendations for the diagnosis and treatment of hypertension issued in 2007. The main elements of novelty refer to the assessment of organ damage, the blood pressure thresholds for treatment initiation as well as the blood pressure goals, the use of drug combination treatment and the therapeutic intervention in specific clinical conditions. This paper will review the novelties of the ESH update document and the implications of the “new guidelines” for current clinical practice.

Cite this article as:

Mancia Giuseppe and Grassi Guido, What Changes we may Expect in 2010 Hypertension Diagnosis and Management: Insights from the European Update Document, Current Vascular Pharmacology 2010; 8 (6) . https://dx.doi.org/10.2174/157016110793563942